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Promoter-Speciﬁc Hypomethylation Is Associated
with Overexpression of PLS3, GATA6, and TWIST1
in the Sezary Syndrome
Henry K. Wong1,2,5, Heather Gibson1,2,5, Timothy Hake1,2, Susan Geyer2,3, Julie Frederickson1,
Guido Marcucci2,3,4, Michael A. Caligiuri2,3,4, Pierluigi Porcu2,3,4 and Anjali Mishra1,2,3,4
The Sézary Syndrome (SS) is an aggressive CD4+ leukemic variant of cutaneous T-cell lymphoma. Epigenetic
modiﬁcation of cancer cell genome is often linked to the expression of important cancer-related genes. Here we
addressed the hypothesis that, in SS, DNA hypomethylation is involved in upregulation of PLS3, GATA6, and
TWIST1, genes that are undetected in normal lymphocytes. Pyrosequencing analysis of CpG rich regions,
and CpG dinucleotides within the 5’ regulatory regions, conﬁrmed hypomethylation of all three genes in
SS, compared with controls. We then studied how methylation regulates PLS3 transcription in vitro using PLS3-
negative (Jurkat) and PLS3-positive (HT-1080) cell lines. Treatment with the hypomethylating agent 5-azacytidine
induced PLS3 expression in Jurkat cells and in vitro methylation of the cloned PLS3 promoter suppressed
luciferase expression in HT-1080 cells. In conclusion, we show that promoter hypomethylation is associated with
PLS3, GATA6, and TWIST1 overexpression in SS CD4+ T cells and that methylation can regulate PLS3 expression
in vitro. The mechanisms of DNA hypomethylation in vivo and the functional role of PLS3, TWIST1, and GATA6 in
SS are being investigated.
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INTRODUCTION
The Sézary Syndrome (SS) is an aggressive variant of
cutaneous T-cell lymphoma (CTCL) characterized by erythro-
derma, lymphadenopathy, and circulating malignant CD4+
T cells, with a 5-year survival of only 26% (Agar et al., 2010).
Not all SS patients initially meet the peripheral blood (PB) and
skin biopsy consensus diagnostic criteria (Olsen et al., 2011)
and the distinction of SS from other erythrodermas can be
very difﬁcult, taking months or years before a deﬁnitive
diagnosis is conﬁrmed and an appropriate treatment is insti-
tuted (Prince et al., 2009).
Studies of malignant CD4+ T cells in SS patients have so
far been conducted on enriched subpopulations of PB
lymphocytes, identiﬁed on ﬂow cytometry through a combi-
nation of immunophenotypical markers, including CD4,
CD45RO, CTLA-4, FoxP3, CD7, CD26, and CD158k, in
combination with clonotypic T-cell receptors (Olsen et al.,
2011). These studies have shown that no single combination
of markers is speciﬁc for SS patients and that tumor cells
(i.e., clone speciﬁc) can be found in immunophenotypically
distinct subsets of T cells in the same patient (Klemke
et al., 2008).
Conventionally, array-based mRNA expression analysis,
microRNA proﬁling, and transcriptome sequencing have led
to the discovery of biomarkers, which have been proposed to
segregate SS––and Mycosis Fungoides––from normal controls
in blood and skin (van Doorn et al., 2004; Vermeer et al.,
2008; Caprini et al., 2009). However, signatures are
inconsistent, and their clinical application in CTCL, while
promising, is still in the very early phase (Mishra and
Porcu, 2011; Wong et al., 2011). Among the transcriptional
abnormalities described in SS, as in other neoplasms
(Rodriguez-Paredes and Esteller, 2011), hypermethylation-
induced silencing of known or candidate tumor suppressor
genes has been proposed to have an important role in the
disease development (Gallardo et al., 2004; van Doorn et al.,
2005), but studies of genome-wide and promoter-speciﬁc
hypomethylation in SS have not been completed.
Here we demonstrate extensive and consistent genome-
wide and promoter-speciﬁc hypomethylation of three
non-lymphoid genes, TWIST1, GATA6, and PLS3, in primary
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SS CD4+ T cells, compared with normal CD4+ T cells.
Notably, SS patient samples that reveal promoter-speciﬁc
hypomethylation also showed increased mRNA levels of
TWIST1, GATA6, and PLS3 compared with normal CD4+
T cells. We also demonstrate that methylation has a direct role
in the transcriptional regulation of PLS3, strongly suggesting
that the observed promoter hypomethylation in primary SS
CD4+ T cells contributes to the aberrant PLS3 upregulation in
SS in vivo. On the basis of the consistent pattern and the
extent of promoter hypomethylation in the primary SS
samples analyzed, we also hypothesize that TWIST1 and
GATA6 are epigenetically upregulated in SS CD4+ T cells.
Our ﬁndings conﬁrm and extend the previously reported role
of methylation in the regulation of PLS3 in SS and support a
previously unreported role for gene-speciﬁc hypomethylation
in the transcriptional upregulation of TWIST1 and GATA6
in SS CD4+ T cells. The mechanisms leading to DNA
hypomethylation, the functional role of TWIST1, GATA6, and
PLS3 in the pathogenesis of SS, and the effects of down-
regulating these genes on SS CD4+ T cells remain unknown
but are currently under investigation.
RESULTS
Genome-scale and promoter methylation analysis of SS patients
To determine epigenetic changes in SS genome, we analyzed
the methylation status of CpG-rich region in genomic DNA of
SS and normal donor (ND) samples through pyrosequencing
(Table 1). Compared with ND CD4+ T cells, methylation
analysis of DNA from SS CD4+ T cells showed a signiﬁcant
genome-wide decrease in the level of DNA methylation
(absolute % methylation in ND vs. SS= 74.58± 0.6337 vs.
61.23± 4.064, N= 6 each) (Figure 1a). Because the expres-
sion of TWIST1, GATA6, and PLS3 is normally highly
regulated during development (Shinomiya, 2012), being
mostly restricted to non lymphoid cells in the adult (Arpin
et al., 1994; Shimizu and Yamamoto, 2005; Li et al., 2011),
and given that abnormal expression in cancer is often asso-
ciated with aberrant gene methylation (Lin et al., 1999; Qin
et al., 2012), we hypothesized that epigenetic mechanisms
could also be responsible for their overexpression in SS
CD4+ T cells. Notably, pyrosequencing-based methylation
analysis in SS CD4+ T cells showed signiﬁcantly decreased
methylation of 5′ regulatory region for TWIST1 (relative %
methylation in ND vs. SS= 99.98±12.39 vs. 58.48± 7.845,
N= 6 each), GATA6 (relative % methylation in ND vs.
SS= 99.91±6.514 vs. 70.73± 11.16, N= 6 each), and PLS3
(relative % methylation in ND vs. SS= 99.94± 14.18 vs.
41.35± 13.73, N= 6 each) compared with ND CD4+ T cells
(Figure 1b and Supplementary Figure S1 and Table S1A
online). Consistent with the promoter analysis, examination of
individual CpG dinucleotides methylation in SS CD4+ T cells
revealed striking hypomethylation in promoter CpG dinucleo-
tides in TWIST1 (11/22 CpG dinucleotide; 50%), GATA6 (2/7
CpG dinucleotide; 28.6%), and PLS3 (8/11 CpG dinucleotide;
72.7%), compared with ND CD4+ T cells (Figures 1c–e,
Supplementary Table S1B online). These experiments show
genome-wide hypomethylation, as well as promoter-speciﬁc
hypomethylation of TWIST, GATA6, and PLS3 in SS patients.
Genes with hypomethylated promoter are highly overexpressed
in SS
On the basis of the data that TWIST1, GATA6, and PLS3
promoter were signiﬁcantly hypomethylated in SS CD4+
T cells, we performed a quantitative expression analysis of
their mRNA, with the goal of focusing on the mechanisms of
its transcriptional regulation. To study the expression of these
genes in other inﬂammatory skin disorders, we measured the
expression levels in PB cells from patients with psoriasis, a
benign T-cell-mediated skin disease. TWIST1, GATA6, and
PLS3 mRNA expression was barely above control in the blood
of six psoriasis patients (Figure 2). Analysis of quantiﬁcation of
RNA expression by semi-quantitative PCR suggests over-
expression of TWIST1 (fold change SS vs. psoriasis= 59.87±
30.13 vs. 3.688± 1.66, N= 6 each), GATA6 (fold change SS
vs. psoriasis=20.42± 5.97 vs. 2.118± 0.57, N= 6 each),
and PLS3 (fold change SS vs. psoriasis= 413.1± 177.8 vs.
1.182± 0.38, N= 6 each) in SS samples compared with ND
(Figure 2 and Supplementary Figure S2 online). Together,
these data show signiﬁcant overexpression of PLS3, TWIST1,
and GATA6 mRNA in SS patients, compared with ND CD4+
T cells.
5-Azacytidine treatments induce the PLS3 mRNA expression
On the basis of previous studies performed in our laboratory
(Tang et al., 2010) and the availability of PLS3− lymphoid
(Jurkat and FSCCL) and PLS3+ non lymphoid (DU145 and
HT-1080) cell lines, we next investigated the regulatory effect
of promoter methylation on PLS3 expression. These cell lines
were selected not as models for SS, but because they replicate
the expression pattern of PLS3 in lymphoid and non-lymphoid
cells and can therefore be used to interrogate the transcrip-
tional regulation of PLS3 in different cell lineages. Further-
more, PLS3 is the gene that showed the highest level of
expression and the greatest level of hypomethylation in our
analysis of SS CD4+ T cells (Figures 1b and 2 and
Supplementary Figure S2 online), and we predicted it to be
the more informative candidate for this study.
Table 1. Demographics of SS patients: for gene
methylation and mRNA expression analysis, PBMCs
were puriﬁed for DNA and RNA isolation, respectively
(data shown in Figures 1 and 2)
SS patient Stage/TNMB Age Sex CD4+ CD26−
SS1 4a/T4N1M0B2 75 AAF 79%
SS2 4a/T4N3M0B2 64 WM 92%
SS3 4a/T4N3M0B2 53 WF 96%
SS4 4a/T4N1M0B2 78 WM 70%1
SS5 4a/T4N1M0B2 71 WM 80.5%
SS6 4a/T4N1M0B2 62 WM 97%
Abbreviations: AAF, African American Female; PBMC, peripheral blood
mononuclear cell; SS, Sézary Syndrome; WM, white male.
1This patient shows loss of normal T-cell markers, including CD4+, but has
a unique population with loss of CD26.
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We conﬁrmed strong expression of PLS3 mRNA (Figure 3a
and Supplementary Figure S3 online) and protein (Figure 3b)
in the non-lymphoid cell lines DU145 and HT-1080 and lack
of expression in the lymphoid cell lines Jurkat and FSCCL.
Next, we designed primers for four CpG rich regions within
the PLS3 promoter sequence to perform HpaII/MspI analysis
and PCR to assess for the differential methylation of the PLS3
gene promoter in the lymphoid (PLS3− ) versus non-lymphoid
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Figure 1. Identiﬁcation of gene methylation signature in Sézary Syndrome (SS) patients, including CpG-speciﬁc analysis. (a) Global DNA methylation levels ND
and SS patients as measured by LINE-1 methylation by pyrosequencing. (b) Percent methylation of speciﬁc promoter region of TWIST1, GATA6, and PLS3 from SS
patients relative to levels in ND controls (arbitrarily set at 100%) is shown as mean± SEM, n=6 each. (c–e) Differential methylation of CpG dinucleotides in
promoter region of TWIST1, GATA6, and PLS3 genes from SS patients (■) relative to promoter methylation levels in normal donor (☐) controls (arbitrarily set at
100%) is shown as mean± SEM, n=6 each. ND, normal donor.
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(PLS3+) cell lines (Figure 3c) (Mi and Roberts, 1992). As
expected, PLS3− cells (Jurkat and FSCCL) exhibited hyper-
methylation of the PLS3 promoter, as conﬁrmed by HpaII/
MspI analysis, whereas in cells that expressed PLS3 (HT-1080
and DU145) the promoter was not methylated (Figures 3d
and e).
We then selected Jurkat cells to further examine the
regulatory role of methylation in the suppression of the PLS3
gene. To determine whether demethylation can induce the re-
expression of PLS3, we treated Jurkat cells with 5-azacytidine.
Remarkably, Jurkat cells treated with 5-azacytidine showed
signiﬁcantly enhanced expression of PLS3 transcript com-
pared with the untreated controls (Po0.001, Figure 3f).
Promoter methylation analysis further corroborated these
ﬁndings as shown by reduced methylation at the PLS3
promoter in 5-azacytidine-treated cells (Figure 3g). These
data demonstrate that Jurkat cells have a silenced PLS3 gene
but are transcriptionally competent for its expression, once
the PLS3 promoter is demethylated. In the context of our
in vivo observations, these results support the hypothesis that
PLS3 overexpression in SS CD4+ T cells is due to promoter
hypomethylation. Consistent with these observations, methy-
lation analysis of PLS3 promoter in patient-derived CTCL cell
line revealed substantial hypo- and hypermethylation in SeAx
and HuT-78 cells, respectively (Supplementary Figure S4A
online), which correlates with the overexpression of
PLS3 transcript in SeAx cells and silencing in Hut-78 cells
(Begue et al., 2012; Supplementary Figure S4B online).
In vitro methylation of PLS3 promoter diminishes reporter gene
activity
To further dissect the role of promoter methylation in
repressing PLS3 expression, we ascertained the transcriptional
activity of cloned PLS3 promoters following in vitro methyla-
tion in PLS3− lymphoid as well as PLS3+ non-lymphoid cells
via luciferase reporter assays. We ﬁrst generated PLS3
promoter plasmid constructs for luciferase reporter assays
with various length of the proximal promoter, from 100 bp to
3 Kb upstream of the transcriptional start site of the gene
(Figure 4a). Luciferase reporter assays of the PLS3 promoter
constructs demonstrated the transcriptional activity of the
0.5 Kb, 1 Kb, and 3 Kb promoters constructs. Although the
0.1 Kb region of promoter was inefﬁcient for transcriptional
activity, the 0.5–3 Kb promoters efﬁciently drove PLS3 gene
transcription, as shown by the luciferase activity in transfected
Jurkat and HT-1080 cells (Figures 4b and c respectively).
Given the demonstration that the promoter region between
0. 5Kb and 3 Kb upstream of transcriptional start site induces
PLS3 gene transcription, we then evaluated the effect of
methylation of these promoter regions in the HT-1,080 cells,
which normally express high levels of PLS3. Relative to
unmethylated controls methylated 0.5 Kb and methylated
3 Kb-transfected HT-1080 cells showed signiﬁcantly reduced
luciferase activity (Figure 4d). These ﬁndings conﬁrm and
extend our observations on the epigenetic regulation of PLS3
expression in Jurkat cells, which could be induced to express
PLS3 by exposure to the demethylating agent 5-azacytidine.
They also suggest that the PLS3 promoter hypomethylation we
observed in vivo is a mechanism for PLS3 upregulation in SS
patients.
DISCUSSION
Earlier studies have identiﬁed gene signatures in the skin and
blood of patients with Mycosis Fungoides and SS and
proposed their value as diagnostic biomarkers. These
signatures have typically combined over- and underexpressed
gene classiﬁers but have generally not provided insights to
explain the mechanism of transcriptional dysregulation
(Nebozhyn et al., 2006a; Narducci et al., 2011; Ralfkiaer
et al., 2011 ). However, the observation of broad abnor-
malities of gene expression in SS raises the hypothesis that a
combination of genome-wide and gene-speciﬁc mechanisms
of transcriptional dysregulation, such as aberrant epigenetic
control, may be involved. The elucidation of these mechan-
isms is likely to provide insights on the molecular steps
important in the development of SS.
As part of an ongoing gene expression analysis in SS, which
revealed overexpression of a number of non-hematopoietic
genes in SS CD4+ T cells, compared with normal CD4+
T cells, the objective of this study was to investigate the
mechanisms responsible for their transcriptional upregulation
and overexpression. We focused on TWIST1, GATA6, and
PLS3, three genes that have been implicated as candidate
oncogenes in several solid tumors, where they are often
epigenetically regulated, but whose expression in normal
lymphoid cells and role in hematologic malignancies have
not yet been fully investigated. On the basis of epigenetic
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Figure 2. Quantitative expression analysis of PLS3, TWIST1, and GATA6 in
Sézary Syndrome (SS) patients. Quantitative gene expression analysis in SS
and psoriasis patients compared with CD4+ ND. Fold change (mean+SEM,
n= 6 each) in TWIST1, GATA6, and PLS3 in SS patients, relative to values
in CD4+ cells from ND. Each measurement was normalized against the
level of β-2 microglobulin. ND values were arbitrarily set at 1. ND, normal
donor.
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models of abnormal gene expression in other lymphoid
neoplasms (De et al., 2013), we hypothesized that genome-
wide and gene-speciﬁc hypomethylation could also be invol-
ved in the aberrant expression of these genes in SS CD4+
T cells.
Here we show that genome-wide and gene-speciﬁc
promoter hypomethylation of DNA obtained from primary
SS CD4+ T cells were observed. Promoter hypomethylation
was not only found in all SS patients tested but was also
“unique” and “speciﬁc” for CpG dinucleotides spanning the
promoter region of each of the three genes. Of additional
signiﬁcance is that these genes are located on different
chromosomes (PLS3 on Xq23, TWIST1 on 7p21, and GATA6
on 18q11.1), indicating that the loss of methylation does not
merely reﬂect altered epigenetic control within a localized
contiguous chromosomal region.
We further demonstrate, through classical in vitro transcrip-
tional studies, the direct regulatory role of DNA methylation
on the expression of one of these genes (PLS3). Thus, our work
uncovers the potential role of gene-speciﬁc DNA hypomethy-
lation in inducing aberrant transcriptional control in SS CD4+
T cells and shows that abnormal epigenetic regulation may
lead to the overexpression of TWIST1, GATA6, and PLS3. In
light of the fact that epigenetic deregulation can precede
classical transforming genetic events such as mutations, gene
ampliﬁcations, and deletions (Feinberg, 2005), our work also
provides the initial evidence to support further genomic
studies in CD4+ T cells from early-stage CTCL patients with
the goal of identifying the factors that lead to gradual loss of
epigenetic regulation in these neoplasms.
Previous investigations into the epigenome of SS patients
have shown that CpG-rich regions in the promoter sequence
of certain genes are prone to hypermethylation, leading to
transcriptional silencing of tumor suppressor genes that may
contribute to the neoplastic phenotype (Gallardo et al., 2004;
van Doorn et al., 2005). The speciﬁc mechanisms of trans-
criptional silencing involve hypermethylation of promoter/
enhancer elements (rich in CpG dinucleotides), changes in
chromatin structure, recruitment of transcriptional repressors,
and interference with the binding of transcriptional activators
(Ehrlich, 2002). van Doorn et al. (2005), identiﬁed hyper-
methylation-induced silencing of the transcription regulatory
region of a series of genes in CTCL that are pivotal in known
cellular pathways, such as cell cycle regulation (p15, p16,
and p73), DNA repair (MGMT), apoptosis (TMS1, and p73),
and chromosome stability (CHFR). In addition, STAT3
activation in CTCL has been linked to the hypermethylation
of the SHP-1 promoter, although conﬂicting data have been
reported (Zhang et al., 2000; McKenzie et al., 2012).
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Figure 3. PLS3 expression in normal donor (ND), Sézary Syndrome (SS), Lymphoid, and non-lymphoid cell lines. (a) RT-PCR analysis of PLS3 mRNA SS, ND,
Jurkat, FSCCL, DU145, and HT-1080 cells. (b) PLS3 protein expression by immune-blot analysis. Actin is included as an internal control. (c) Schematic of PLS3
gene with restriction sites (red) and PCR ampliﬁcation regions (black) for methylation analysis by HpaII/MspI digestion. (d) Methylation-speciﬁc PCR using
primers deﬁned above. A control region, C, contains no digest sites. (e) Analysis of PLS3 promoter by methylation-speciﬁc PCR/digest (f) RT-PCR on Jurkat cells
treated with 5-Azacytidine. Results are presented, shown as mean ± SEM of three independent experiments. (g) Differential methylation of CpG dinucleotides in
PLS3 promoter in Jurkat cells treated with either DMSO (white bar) or 5-Azacytidine (black bar) for 48 hours. RT-PCR, reverse transcriptase–PCR.
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The role of hypomethylation in the regulation of gene
expression in SS, however, has thus far not been widely
investigated. To the best of our knowledge, our study is the
ﬁrst to show that the genome of SS CD4+ T cells is
signiﬁcantly hypomethylated compared with ND CD4+
T cells and that promoter-speciﬁc hypomethylation is asso-
ciated with simultaneous PLS3, TWIST1, and GATA6
upregulation. Recently, Jones et al. reported observing
hypomethylated PLS3 promoter in SS patients at CpG
dinucleotides 95–99 (Jones et al., 2012). However, the
impact of these changes on the transcriptional regulation of
PLS3 was not ascertained. Our study shows much broader
hypomethylation of the PLS3 gene in SS patients––i.e., 8 out
of 11 CpG dinucleotides were signiﬁcantly hypomethylated
compared with ND CD4+ T cells. In addition, we have
dissected the regulatory effect of PLS3 promoter methylation
and demethylation on its transcription using functional
luciferase reporter assays, thus asserting a direct correlation
between promoter methylation and gene transcription.
Although a larger expression and epigenetic analysis is
ongoing in our laboratory, the sample size in this study does
not allow us to assess the prevalence of overexpression and
promoter hypomethyation of the TWIST1, GATA6, and PLS3
genes in SS. However, other large gene expression studies
have all shown that PLS3 and TWIST1 are overexpressed in the
majority of the SS samples analyzed (van Doorn et al., 2004;
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Nebozhyn et al., 2006b), suggesting that our observations
have relevance beyond the patient population of this study.
We also cannot rule out the existence of other mechanisms for
the overexpression of these genes in SS, such as gene
ampliﬁcation, chromosomal translocations, and decreased
mRNA degradation. The chromosomal region that hosts the
TWIST1 locus on 7p21 has been found to be ampliﬁed in some
comparative genomic hybridization studies in a subset of
patients with SS (Vermeer et al., 2008). The same, however,
has not been observed for PLS3 and GATA6.
A direct role of hypomethylation in T-cell lymphoma
pathogenesis is supported by a study in which investigators
created a hypomorphic allele for DNA methyltrasferase 1
(Dnmt1) that reduces its expression to 10% of that for
wild type (Gaudet et al., 2003). Interestingly, 80% of the mice
with hypomethylated genome developed mature T-cell
lymphomas, with a high prevalence of chromosome 15
trisomy. Although there are several hypotheses explaining the
role of hypomethylation in tumorigenesis, the major
carcinogenic effect of hypomethylation is thought to be its
ability to induce genomic instability. Genomic hypomethyla-
tion may also facilitate incorrect mitotic recombination that
then leads to chromosomal breaks, translocations, and/or
allelic loss (Gronbaek et al., 2007; Karenko et al., 2007). The
hypomethylated tumors also exhibited a higher prevalence of
duplicated and deleted chromosome regions. Further research
is needed to fully understand the role and mechanism of
genomic hypomethylation in the pathogenesis of SS.
The functional consequences of overexpression of TWIST1,
GATA6, and PLS3 in the pathogenesis of SS remain to be
determined. Earlier studies have shown that TWIST1 is an
oncogene that collaborates with c-MYC to induce tumorigen-
esis and has a critical role in inhibiting cell apoptosis by
inactivating the ARF/p53 pathway (Puisieux et al., 2006). In
mouse lymphocytes, expression of TWIST1 has been shown
to suppress the expression of the Th1 transcriptional regulators
T-bet, Runx3, and IL-12Rb, leading to decreased production of
IFNg (Pham et al., 2012). Finally, TWIST1 can be directly
targeted for upregulation by STAT3 (Qin et al., 2012), an
important driver of CTCL pathogenesis (McKenzie et al., 2012).
Similarly, overexpression of GATA6 has been implicated in
oncogenesis by increasing the Wnt signaling pathway (Zhong
et al., 2011). Finally, a recent study suggested that PLS3
overexpression confers anti-apoptotic properties to T cells
along with an increase in their migration properties (Begue
et al., 2012). Thus, PLS3 overexpression may have implications
for the survival and trafﬁcking of T cells in SS.
In summary, our detailed analysis of aberrant overexpres-
sion and hypomethylation of TWIST1, GATA6, and PLS3 in SS
patients and the functional data from the PLS3 promoter
reporter assays provide the proof-of-concept evidence that
hypomethylation is involved in abnormal gene expression in
SS. The strong correlation between the aberrant expression of
TWIST1, GATA6, and PLS3 and their promoter hypomethyla-
tion in SS patients further endorses understanding of the
nature of epigenetic modiﬁcation in malignant T cells and
supports the study of their oncogenic potential in SS.
MATERIALS AND METHODS
Patient samples and isolation of CD4+ Cells
PB mononuclear cells were obtained from patients with SS and from
NDs after informed consent. The Institutional Review Board of Henry
Ford Hospital and the Ohio State University Comprehensive Cancer
Center approved this study. SS was diagnosed according to the ISCL/
EORTC criteria2. Patients with high levels of PB atypical lymphocytes
were selected for further experiments (Table 1). ND CD4+ T cells
were puriﬁed by negative selection using the EasySep Human
Memory CD4+ T-Cell Enrichment Kit (STEMCELL, Vancouver, BC,
Canada) as per manufacturer’s instructions.
RNA and DNA extraction
Approximately 5–10×106 cells were used for nucleic acid extraction
using either the RNeasy Mini Kit or the DNeasy kit (Qiagen,
Valencia, CA) as per manufacturer’s protocol.
Complementary DNA synthesis and real-time PCR
For PCR, 1 μg total RNA was transcribed to complementary DNA using
the Superscript First-Strand Synthesis kit (Invitrogen, Grand Island,
NY) as per manufacturer instruction. Reverse transcriptase–PCR was
performed using Fast 2X SYBR green PCR mix (Applied Biosystems,
Austin, TX). β-2 microglobulin was used for data normalization.
DNA methylation analysis
EpigenDx (EpigenDx, Inc, Hopkinton, MA) performed DNA methyla-
tion analysis. Brieﬂy, bisulphite modiﬁcation of 500 ng genomic DNA
from SS patient and ND was performed using the Zymo Research EZ
Methylation Gold kit (Zymoresearch, Irvine, CA) followed by the PCR
ampliﬁcation and pyrosequencing. Methylation quantiﬁcation was
performed using the PSQt96HS system (Biotage, Charlotte, NC).
Cell culture and drug treatment
DU145, HT-1080, Jurkat, HuT-78, and FSCCL cell lines were
cultured as described by ATCC. SeAx cells were kindly provided
by Dr. Niels Odum (University of Copenhagen) and maintained
as previously described (Kaltoft et al., 1987). For in vitro assay,
approximately 1×106 Jurkat cells were incubated with 0.1 μM and
1 μM 5-Azacytidine (Sigma-Aldrich, St Louis, MO) for 48 and
72 hours. Cells were harvested for DNA and RNA extraction for
promoter methylation and gene expression analysis.
Cloning and transfection of PLS3 promoter
For the promoter activity assay, the human PLS3 (transcript variant 1,
NM_–5032) promoter was ampliﬁed by PCR. The PCR products were
cloned into pGEM-T easy and subcloned into the pGL3 luciferase
reporter plasmid (Promega, Madison, WI) using SacI and BglII
restriction sites added to the forward and reverse primers, respec-
tively. For transfection, Jurkat and HT-1080 cells were transfected
with PGL3 luciferase vectors containing 3 Kb, 1 Kb, 0.5 Kb, and
0.1 Kb fragment of 5’ region of the human PLS3 gene. Brieﬂy,
approximately 2× 106 cells were transfected with 2 μg DNA using
Lipofectin reagent (Invitrogen) as per manufacturer’s protocol. Cells
were harvested for the luciferase assay 12–24 hours post transfection.
Luciferase assay
The luciferase assay was performed as described in Current Protocols
in Molecular Biology. Brieﬂy, cells were lysed in luciferase lysis
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buffer with 1mM dithiothreitol. Overall, 50 μl lysate was added to
300 μl luciferase reaction mixture. Luciferin was added to make a
ﬁnal concentration of 150 μM, followed by immediate luminescence
detection and normalized against cell lysates of cells transfected with
promoterless PGL3 basic vector (Promega).
Statistical analysis
Summary statistics were calculated for markers in each group (i.e.,
ND vs. psoriasis patients vs. SS patients). Graphical analyses such as
side-by-side boxplots were also used to assess trends and differences
in markers between groups. Comparisons between two groups (e.g.,
ND vs. SS patients or psoriasis vs. SS patients) used Wilcoxon rank-
sum tests and comparisons between three groups (ND vs. psoriasis
patients vs. SS patients) used Kruskal–Wallis tests. Statistical
signiﬁcance was declared at Po0.05; multiple comparison correc-
tions were not utilized given the limited sample size and overall
exploratory nature of these analyses. Data were analyzed using the
statistical program R (version 2.15.2 GUI 1.53 Leopard build 64-bit),
as well as GraphPad Prism (GraphPad Software, La Jolla, CA)
statistical software.
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